C. diff Risk


Oral Bioavailability


Approximate Cost



General Pediatric

30 mg/kg/24h IV/ divided q12h
Maximum:1 g/24h
3 Months - 12 Years

1 g IV q24h
12+ Years


Renally cleared, requires dosage adjustment with changes in renal function. Consult a pharmacist for renal dosing.

General Information

Common Usage

Targeted therapy of ESBL infections and other resistant gram negative infections. Empiric therapy when broad spectrum of carbapenems is desired without the need for anti-pseudomonal activity

Drug Monitoring

  • Renal Function

  • Hepatic function

  • CBC

Adverse Effects

  • Immediate and delayed-type allergy

  • GI disturbance

  • Cytopenias, eosinophilia, positive Coombs

  • Liver enzyme abnormalities

Additional Information

ID consult recommended. Doesn't reliably penetrate CNS therefore not recommended for meningitis.


Antimicrobial class: Carbapenem

Route of Elimination:

  • Non-CYP-mediated hydrolysis to inactive metabolite.

  • Urine (80%(38% as unchanged drug)) and feces (10%)

Average serum half life:

  • Infants 3 months and older, and children: 2.5hrs

  • Adolescents and Adults: 4 hrs